Business Context and Reporting Period
Company: Humacyte, Inc. (HUMA)
Filing Type: Form 8-K (Current Report)
Date of Report: December 15, 2025
Event: Termination of a Material Definitive Agreement and concurrent Registered Direct Offering.
Key Financial Metrics and Transaction Details
This filing reports a specific transaction rather than periodic financial performance. No revenue, profit, or cash flow metrics for a reporting period are provided in this document.
- Termination Consideration (Cash): $38 million payable to Purchasers (TPC Investments III LP and TPC Investments Solutions LP).
- Termination Consideration (Equity): 5,725,190 shares of Common Stock to be issued to Purchasers.
- Funding Source: The $38 million cash payment is expected to be funded by proceeds from a new credit facility.
- Securities Issued: Common Stock (HUMA) and Redeemable Warrants (HUMAW) are registered on Nasdaq.
Material Changes and Agreements
On December 15, 2025, the Company and Humacyte Global, Inc. terminated the following agreements with the Purchasers:
- Revenue Interest Purchase Agreement: Dated May 12, 2023, as amended.
- Option Agreement: Dated May 12, 2023.
The termination satisfies all obligations under these agreements. The transaction involves a registered direct offering pursuant to an effective Form S-3 shelf registration statement (File No. 333-290231) declared effective on September 22, 2025.
Outlook, Risks, and Management Commentary
Closing Conditions: The Offering is expected to close on December 15, 2025, subject to the satisfaction of customary closing conditions.
Legal Opinion: An opinion regarding the validity of the Shares to be issued has been provided by Covington & Burling LLP.
Emerging Growth Company Status: The registrant is an emerging growth company and has not elected to use the extended transition period for new accounting standards.
Investor Verification Checklist
- Verify the closing of the Registered Direct Offering and the issuance of 5,725,190 shares.
- Confirm the execution and terms of the new credit facility intended to fund the $38 million cash payment.
- Review the impact of the terminated Revenue Interest Purchase Agreement on future revenue recognition and financial obligations.
- Check for any dilution effects resulting from the issuance of new shares to TPC Investments.